A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR PLUS EF

洛匹那韦/利托那韦加 EF 的 III 期、随机、开放标签比较

• 批准号: 7606755
• 负责人: MARGRIT E CARLSON
• 金额: $ 0.77万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606755
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Failure; Funding; Grant; Institution; Label; Lamivudine; Lopinavir/Ritonavir; Phase; Randomized; Research; Research Personnel; Resources; Source; Time; Toxic effect; Treatment Protocols; United States National Institutes of Health; Zidovudine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives are: 1. To compare the time to virologic failure pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. (See Section 3.5 for definition of virologic failure.) 2. To compare the time to regimen completion pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. See sections 3.5 and 3.6 for definition of virologic failure and regimen completion.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目标是： 1。将三个治疗组之间的时间与病毒衰竭进行比较：LPV/R Plus EFV，LPV/R Plus D4T XR（或ZDV）加上3TC和EFV加上D4T XR（或ZDV）加上3TC。 （有关病毒衰竭的定义，请参见第3.5节。） 2。将三个治疗组之间的方案完成的时间进行比较：LPV/R Plus EFV，LPV/R Plus D4T XR（或ZDV）加上3TC，EFV加上D4T XR（或ZDV）加上3TC。 治疗方法的完成将定义为对初始随机治疗方案的任何组成部分的病毒学衰竭或与毒性相关的停用。 有关病毒衰竭和疗法完成的定义，请参见第3.5和3.6节。